GERON CORP Total Liabilities
GERON CORP (GERN) had Total Liabilities of $300.39 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-05
- 2026-06-30: Liabilities $300.39M.
- 2026-03-31: Liabilities $305.01M.
- 2025-12-31: Liabilities $344.67M.
- 2024-12-31: Liabilities $313.46M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $300.39M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $305.01M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $344.67M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $313.46M 10-K · filed 2026-03-02 |
| 2023-12-31 | $146.13M 10-K · filed 2025-02-27 |
| 2022-12-31 | $110.58M 10-K · filed 2024-02-28 |
| 2021-12-31 | $99.62M 10-K · filed 2023-03-16 |
| 2020-12-31 | $59.78M 10-K · filed 2022-03-10 |
| 2020-09-30 | $52.96M 10-Q · filed 2020-11-05 |
| 2019-12-31 | $30.36M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |